These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 30973654)

  • 1. RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy.
    Mini E; Lapucci A; Perrone G; D'Aurizio R; Napoli C; Brugia M; Landini I; Tassi R; Picariello L; Simi L; Mancini I; Messerini L; Magi A; Pinzani P; Mazzei T; Tonelli F; Nobili S
    Int J Cancer; 2019 Nov; 145(9):2580-2593. PubMed ID: 30973654
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Lapucci A; Perrone G; Di Paolo A; Napoli C; Landini I; Roviello G; Calosi L; Naccarato AG; Falcone A; Bani D; Mini E; Nobili S
    Oncol Res; 2021 Mar; 28(6):631-644. PubMed ID: 33208224
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
    World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
    Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Huh I; Park T; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
    Cancer; 2017 Sep; 123(18):3513-3523. PubMed ID: 28513830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
    Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
    BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer.
    Cao B; Luo L; Feng L; Ma S; Chen T; Ren Y; Zha X; Cheng S; Zhang K; Chen C
    BMC Cancer; 2017 Dec; 17(1):844. PubMed ID: 29237416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A network-based predictive gene expression signature for recurrence risks in stage II colorectal cancer.
    Yang WJ; Wang HB; Wang WD; Bai PY; Lu HX; Sun CH; Liu ZS; Guan DK; Yang GW; Zhang GL
    Cancer Med; 2020 Jan; 9(1):179-193. PubMed ID: 31724326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
    Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
    Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer.
    Matsuyama T; Kandimalla R; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kinugasa Y; Hansen TF; Fakih M; Uetake H; Győrffy B; Goel A
    Int J Cancer; 2020 Dec; 147(11):3250-3261. PubMed ID: 32657428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
    Dienstmann R; Villacampa G; Sveen A; Mason MJ; Niedzwiecki D; Nesbakken A; Moreno V; Warren RS; Lothe RA; Guinney J
    Ann Oncol; 2019 Oct; 30(10):1622-1629. PubMed ID: 31504112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.
    Bruun J; Sveen A; Barros R; Eide PW; Eilertsen I; Kolberg M; Pellinen T; David L; Svindland A; Kallioniemi O; Guren MG; Nesbakken A; Almeida R; Lothe RA
    Mol Oncol; 2018 Sep; 12(9):1639-1655. PubMed ID: 29900672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer.
    Reggiani Bonetti L; Barresi V; Maiorana A; Manfredini S; Caprera C; Bettelli S
    Dis Markers; 2018; 2018():2959801. PubMed ID: 30018674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype.
    Kwon Y; Park M; Jang M; Yun S; Kim WK; Kim S; Paik S; Lee HJ; Hong S; Kim TI; Min B; Kim H
    Oncotarget; 2017 Jun; 8(24):39367-39381. PubMed ID: 28455965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy.
    Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
    BMC Cancer; 2019 May; 19(1):421. PubMed ID: 31060539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical assessment and identification of immuno-oncology markers concerning the 19-gene based risk classifier in stage IV colorectal cancer.
    Lee JL; Roh SA; Kim CW; Kwon YH; Ha YJ; Kim SK; Kim SY; Cho DH; Kim YS; Kim JC
    World J Gastroenterol; 2019 Mar; 25(11):1341-1354. PubMed ID: 30918427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
    Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
    Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
    [No Abstract]   [Full Text] [Related]  

  • 18. A formalin-fixed paraffin-embedded (FFPE)-based prognostic signature to predict metastasis in clinically low risk stage I/II microsatellite stable colorectal cancer.
    Low YS; Blöcker C; McPherson JR; Tang SA; Cheng YY; Wong JYS; Chua C; Lim TKH; Tang CL; Chew MH; Tan P; Tan IB; Rozen SG; Cheah PY
    Cancer Lett; 2017 Sep; 403():13-20. PubMed ID: 28624625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer.
    Takahashi M; Cuatrecasas M; Balaguer F; Hur K; Toiyama Y; Castells A; Boland CR; Goel A
    PLoS One; 2012; 7(10):e46684. PubMed ID: 23056401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival marker genes of colorectal cancer derived from consistent transcriptomic profiling.
    Martinez-Romero J; Bueno-Fortes S; Martín-Merino M; Ramirez de Molina A; De Las Rivas J
    BMC Genomics; 2018 Dec; 19(Suppl 8):857. PubMed ID: 30537927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.